Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

However, it may cover Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and can help manage treatment-resistant depression. Despite not yet having FDA ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

The FDA has approved Janssen’s antidepressant ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen ...

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...

The FDA has cleared Auvelity (dextromethorphan ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

China: A recent randomized clinical trial has highlighted the potential benefits of intraoperative esketamine in reducing postpartum depression (PPD) among women undergoing cesarean delivery. The ...

Engaging in any amount of physical activity reduced the risk for falls among older women, according to a study published in the American Journal of Preventive Medicine.

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news ...